WO2009019473A1 - Treatments for inflammatory arthritis - Google Patents
Treatments for inflammatory arthritis Download PDFInfo
- Publication number
- WO2009019473A1 WO2009019473A1 PCT/GB2008/002671 GB2008002671W WO2009019473A1 WO 2009019473 A1 WO2009019473 A1 WO 2009019473A1 GB 2008002671 W GB2008002671 W GB 2008002671W WO 2009019473 A1 WO2009019473 A1 WO 2009019473A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- imiquimod
- derivative
- pharmaceutically acceptable
- acceptable salt
- agent
- Prior art date
Links
- 206010003246 arthritis Diseases 0.000 title claims abstract description 30
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 30
- 238000011282 treatment Methods 0.000 title abstract description 20
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims abstract description 67
- 229960002751 imiquimod Drugs 0.000 claims abstract description 65
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 13
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 13
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 10
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 10
- 150000003431 steroids Chemical class 0.000 claims description 8
- 239000003018 immunosuppressive agent Substances 0.000 claims description 6
- 229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 claims description 5
- 239000003420 antiserotonin agent Substances 0.000 claims description 5
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 239000002855 microbicide agent Substances 0.000 claims description 5
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims description 5
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 5
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims description 4
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 claims description 4
- 108091030071 RNAI Proteins 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 239000003124 biologic agent Substances 0.000 claims description 4
- 229960001653 citalopram Drugs 0.000 claims description 4
- 229960000389 fluoxetine hydrochloride Drugs 0.000 claims description 4
- 230000009368 gene silencing by RNA Effects 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 claims description 4
- 229960003955 mianserin Drugs 0.000 claims description 4
- 229960001836 promazine hydrochloride Drugs 0.000 claims description 4
- JIVSXRLRGOICGA-UHFFFAOYSA-N promazine hydrochloride Chemical compound [H+].[Cl-].C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 JIVSXRLRGOICGA-UHFFFAOYSA-N 0.000 claims description 4
- 229960001860 salicylate Drugs 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 4
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 4
- 229960002073 sertraline Drugs 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 3
- 238000007911 parenteral administration Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 description 18
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 17
- 210000002540 macrophage Anatomy 0.000 description 16
- 230000006433 tumor necrosis factor production Effects 0.000 description 16
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 11
- 229950005634 loxoribine Drugs 0.000 description 11
- FHJATBIERQTCTN-UHFFFAOYSA-N 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC=CC2=C(N(C(CNCC)=N3)CC(C)(C)O)C3=C(N)N=C21 FHJATBIERQTCTN-UHFFFAOYSA-N 0.000 description 10
- 229940124670 gardiquimod Drugs 0.000 description 10
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 9
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 210000001258 synovial membrane Anatomy 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108010040721 Flagellin Proteins 0.000 description 4
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 4
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 3
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000003456 Juvenile Arthritis Diseases 0.000 description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229940029575 guanosine Drugs 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 239000012480 LAL reagent Substances 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 2
- 229960005207 auranofin Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000420 gastrotoxicity Toxicity 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 229940015045 gold sodium thiomalate Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229950010550 resiquimod Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 206010073931 Genital herpes simplex Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- ZWELIJXAKMASLK-UGKPPGOTSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(5-amino-2-oxo-[1,3]thiazolo[4,5-d]pyrimidin-3-yl)-2-(hydroxymethyl)oxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(=O)C)[C@@H](CO)O[C@H]1N1C(=O)SC2=CN=C(N)N=C21 ZWELIJXAKMASLK-UGKPPGOTSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940060265 aldara Drugs 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940124347 antiarthritic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940009100 aurothiomalate Drugs 0.000 description 1
- XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- -1 colourants Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 102000026898 cytokine binding proteins Human genes 0.000 description 1
- 108091008470 cytokine binding proteins Proteins 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 150000002343 gold Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 229940087652 vioxx Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Definitions
- the present invention relates to imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof for use in treating inflammatory arthritis and related conditions.
- the present invention also relates to the use of imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating inflammatory arthritis and related conditions.
- the present invention also relates to a kit comprising a pharmaceutical composition comprising imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof and instructions indicating that the composition is for use in treating inflammatory arthritis and related conditions.
- the present invention relates to a method of treating inflammatory arthritis and related conditions comprising administration of imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof. The method is preferably carried out on a subject in need of treatment.
- the inflammatory arthritis is preferably rheumatoid arthritis.
- Rheumatoid arthritis is a chronic inflammatory disease occurring in 0.5%-l% of the population. This disease affects the joints and is characterized by thickening of the synovial membrane. This disease leads to progressive debilitation in joint function which results in pain, disability, loss of man power and shorter life expectancy. In addition there are a number of similar related conditions; psoriatic arthritis, juvenile arthritis, ankylosing spondelytis, Crohn's disease and psoriasis.
- steroids such as dexamethasone and methyl-prednisolone
- steroids are widely used in the treatment of rheumatoid arthritis. While treatment with steroids can be effective, there are a number of serious side effects.
- anti-TNF therapy also prevents joint destruction and thus is considered to have disease modifying anti-arthritic drug (DMARD) activity.
- DMARD disease modifying anti-arthritic drug
- it is extremely expensive and this places a heavy financial burden either on the patient or the healthcare system or both and this seriously limits availability.
- Many patients in the developed world and the majority in the developing world are not able to afford this treatment.
- possible side effects of anti-TNF therapy include anaphylaxis and cytopenia.
- systemic neutralisation of TNF leads to increased susceptibility to infection and the long-term effects are still unknown.
- anti- TNF drugs orally which is a disadvantage.
- those patients that do respond approximately 50% will become refractory to treatment in 2 years due to the development of immunity to the biological treatment.
- DARDS disease modifying anti-rheumatic drugs
- methotrexate an anti-metabolite drug, which is widely used for the treatment of rheumatoid arthritis, psoriatic arthritis and psoriasis.
- Methotrexate has been successful in the treatment of these diseases, but can cause substantial side effects, such as severe skin reaction, infections such as pneumonia, severe damage to liver, kidneys, lungs and gastrointestinal tract. Again a significant number of patients do not respond or become refractory with time.
- a number of DMARD pharmaceutical agents containing gold are also used in the treatment of rheumatoid arthritis.
- examples of such agents include gold sodium thiomalate and auranofin.
- Potential side effects from being treated with antiinflammatory gold agents are oral ulcers, altered taste, serious skin rashes, renal problems, inflammation of the intestines (enterocolitis), liver injury and lung disease. Furthermore, resistance to gold has been known to develop in patients.
- a further class of drugs are the non-steroidal anti-inflammatory drugs (NSAID's). These are used to alleviate symptoms but not modify disease progression and includes the Cox 2 inhibitors "VIOXX” ® , (a registered trademark of Merck & Co., Inc) and "CELEBREX” ® , (a registered trademark of G.D. Searle & Co). However there is major concern about the safety of these drugs with evidence of increased cardiovascular risk.
- NSAID's non-steroidal anti-inflammatory drugs
- the first aspect of the present invention provides imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof for use in treating inflammatory arthritis and related conditions.
- ALDARA Imiquimod
- derivatives of imiquimod have the following structure:
- R 1 is -R 2 , -OR 2, -NR 2 R 3 , -R 2 C(O)OR 2 or -R 2 OC(O)R 2 ;
- R 2 is a) alkyl, alkenyl or alkynyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxy, aryl, heteroaryl, carbocycle or heterocycle, wherein the aryl, heteroaryl, carbocycle or heterocycle is optionally substituted by one or more groups independently selected from C]. 6 alkyl, C 1-6 alkoxy and halogen; or b) 5 to 7 membered aryl, heteroaryl, carbocycle or heterocycle, optionally substituted by one or more groups independently selected from C 1-6 alkyl, C 1-6 alkoxy and halogen; and
- R 3 is hydrogen or R 2 .
- Imiquimod comprises the formula set out above wherein R 1 is isobutyl.
- alkyl as used herein means a straight or branched chain saturated hydrocarbon group, preferably with 1 to 10 carbons, more preferably 1 to 6 carbons, most preferably iso-butyl.
- alkene as used herein means a straight or branched chain unsaturated hydrocarbon group containing at least one carbon-carbon double bond. An alkene preferably has 2 to 10 carbons, more preferably 2 to 6 carbons.
- alkyne as used herein means a straight or branched chain unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, preferably with 2 to 10 carbons, more preferably 2 to 6 carbons.
- carbocycle as used herein means a cyclic hydrocarbon group which may be saturated or may contain one or more units of un-saturation, but which is not aromatic.
- a carbocycle is preferably 5-7 membered.
- heterocycle means a cyclic group containing one or more species of heteroatom selected from the group consisting of a nitrogen atom, a sulphur atom and an oxygen atom.
- a heterocyclic group may be unsaturated or may contain one or more units of un-saturation, but is not aromatic.
- a heterocycle is preferably 5-7 membered.
- aryl group used herein means an aryl group constituted by 5 to 10 carbon atoms, which may be monocyclic or bicyclic. Preferably, an aryl is 5-7 membered.
- heteroaryl as used herein means an aromatic cyclic group containing one or more species of heteroatom selected from the group consisting of a nitrogen atom, a sulphur atom and an oxygen atom.
- a heteroaryl is 5-7 membered.
- halogen as used herein means preferably fluorine, chlorine, bromine or iodine.
- Imiquimod or a derivative thereof may be provided as a pharmaceutically acceptable salt.
- the inflammatory arthritis includes rheumatoid arthritis and the related conditions psoriatic arthritis, juvenile arthritis, ankylosing spondelytis but drugs are envisaged to be useful for other chronic diseases driven by TNF such as, Crohn's disease and psoriasis.
- the inflammatory arthritis is rheumatoid arthritis and the related conditions are psoriatic arthritis, juvenile arthritis, ankylosing spondelytis, Crohn's disease and psoriasis.
- Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof according to the present invention inhibit TNF production.
- Imiquimod and/or a derivative thereof and/or a pharmaceutically acceptable salt thereof and/or another agent may be used in combination, which may be for simultaneous, separate or sequential use.
- imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof can be for topical administration.
- imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof can be for oral administration.
- the oral administration of imiquimod can be in combination with an agent that reduces the gastrotoxicity associated with imiquimod.
- the agent can be a prodrug of TLR7 agonists, such as ANA-975.
- Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof and an agent that reduces gastrotoxicity may be for simultaneous, separate or sequential use.
- Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof may be used in combination with a further anti-inflammatory agent.
- Administration of imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof and other anti-inflammatory agent can be simultaneous, separate and/or sequential.
- Imiquimod, derivatives and/or salts thereof, in combination with another pharmaceutical agent can act additively or synergistically.
- the other anti-inflammatory agent may be termed a 5-HT receptor antagonist including promazine hydrochloride, ketanserine tartrate or mianserine hydrochloride, a serotonin reuptake inhibitor including fluoxetine hydrochloride, citalopram or sertraline, an interferon inhibitor, a non-steroidal anti-inflammatory agent (NSAID), a disease modifying anti-rheumatic drug (DMARD), a biological agent (biologicals), a steroid, an immunosuppressive agent, a salicylate and/or a microbicidal agent.
- NSAID non-steroidal anti-inflammatory agent
- DMARD disease modifying anti-rheumatic drug
- biological agent biological agent
- steroid an immunosuppressive agent
- a salicylate and/or a microbicidal agent.
- Nonsteroidal anti-inflammatory agents include anti-metabolite agents (including methotrexate) and anti-inflammatory gold agents (including gold sodium thiomalate, aurothiomalate or gold salts, such as auranofin).
- Biologicals include anti-TNF agents (including adalimumab, etanercept, infliximab, anti-EL-1 reagents, anti-IL-6 reagents, anti-B cell reagents (retoximab), anti-T cell reagents (anti-CD4 antibodies), anti-IL-15 reagents, anti-CLTA4 reagents, anti-RAGE reagents), antibodies, soluble receptors, receptor binding proteins, cytokine binding proteins, mutant proteins with altered or attenuated functions, RNAi, polynucleotide aptamers, antisense oligonucleotides or omega 3 fatty acids.
- Steroids include cortisone, prednisolone or dexamethasone.
- Immunosuppressive agents include cylcosporin, FK506, rapamycin, mycophenolic acid.
- Salicylates include aspirin, sodium salicylate, choline salicylate and magnesium salicylate.
- Microbicidal agents include quinine and hydroxychloroquine.
- imiquimod and derivatives may be administered in combination with one or more of a 5-HT receptor antagonist, a serotonin reuptake inhibitor, an NSAID, DMARD or immunosuppressant.
- the further anti-inflammatory agent is administered orally (including buccally or sublingually) or parenterally (including subcutaneously, intramuscularly, intravenously or intradermally).
- the invention provides the use of imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating inflammatory arthritis and related conditions.
- the second aspect is a kit comprising a pharmaceutical composition comprising imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof and instructions indicating that the composition is for use in treating inflammatory arthritis and related conditions.
- Compositions in accordance with the invention may be supplied as part of a sterile, pharmaceutical composition which will normally include a pharmaceutically acceptable carrier.
- This pharmaceutical composition may be in any suitable form. It may be provided in unit dosage form and will generally be provided in a sealed container.
- the kit of the invention may comprise a plurality of said unit dosage forms.
- the oral pharmaceutical compositions may be presented as discrete units such as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids; or as edible foams or whips; or as emulsions).
- Suitable excipients for tablets or hard gelatine capsules include lactose, maize starch or derivatives thereof, stearic acid or salts thereof.
- Suitable excipients for use with soft gelatine capsules include for example vegetable oils, waxes, fats, semi-solid, or liquid polyols etc.
- excipients which may be used include for example water, polyols and sugars.
- suspensions oils e.g. vegetable oils
- oil-in-water or water in oil suspensions may be used.
- compositions may contain preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts, buffers, coating agents or antioxidants. They may also contain further therapeutically active agents.
- Route of administration may include; parenterally (including subcutaneous, intramuscular, intravenous, by means of, for example a drip patch), some further suitable routes of administration include (but are not limited to) oral (including buccal and sublingual), rectal, nasal, topical, infusion, vaginal, intradermal, intraperitoneally, intracranially, intrathecal and epidural administration or administration via oral or nasal inhalation, by means of, for example a nebuliser or inhaler, or by an implant.
- the oral or nasal inhalation routes may be delivered using a mechanical form including, but not restricted to, an inhaler or nebuliser device.
- administration is by a SPAG (small particulate aerosol generator) may be used.
- SPAG small particulate aerosol generator
- Dosages of the substances of the present invention can vary between wide limits, depending upon the condition to be treated, the health of the individual to be treated, etc. and a physician may determine appropriate dosages to be used. The dosage may be repeated as often as appropriate.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the imiquimod or derivative which produces a therapeutic effect
- compositions and uses described in this application are envisaged to have human, animal and veterinary applications. They are preferably applicable to mammals, in particular humans but are also applicable for use in production animals, in particular sheep, cows, pigs, chickens and goats, as well as companion animals, in particular cats and dogs and sporting animals, such as horses.
- the third aspect of the invention is a method of treating inflammatory arthritis and related conditions comprising administering imiquimod, a derivative or a salt thereof.
- the derivative is defined according to the first aspect of the invention.
- the method is preferably carried out on a subject in need of treatment.
- the term "treatment” includes prophylactic treatment (i.e. prevention). In most circumstances, prevention of inflammatory arthritis or a related condition is unlikely to be carried out. Usually, it is only when the presence of inflammatory arthritis or a related condition is diagnosed in a subject that prevention means are applied. However, prophylactic treatment may be appropriate if there is a known family history of significant inflammatory arthritis or a related condition or if tests (e.g. genetic tests) identify that an individual has a predisposition to inflammatory arthritis or a related condition.
- the fourth aspect of the invention is imiquimod, a derivative or a salt thereof for treating inflammatory arthritis or a related condition.
- Figure 1 illustrates that imiquimod inhibits, R-848 increases and CpG has no effect on spontaneous TNF production from rheumatoid synovial cultures. Levels of TNF production are shown in ng/ml ⁇ SEM from 7 - 12 unrelated RA patients.
- FIG. 2 illustrates that gardiquimod enhances spontaneous TNF production in rheumatoid synovial cultures.
- RA synovial membrane cells were incubated for 24 hours in the presence of media alone or media containing 1 or 5 ⁇ g/ml gardiquimod (gard).
- Figure 3 illustrates that imiquimod selectively inhibits activation of TLR8 signaling -
- (a) Primary human M-CSF macrophages were incubated with 10 ⁇ g/ml imiquimod alone or in combination with 10 ng/ml Flagellin, 10 ng/ml Pam3, 1 ⁇ g/ml R-848 or 10 ng/ml LPS for 6 hours. Data was pooled from triplicate wells from 3 separate donors and shown as a percentage of the appropriate maximal responses (100%).
- M-CSF macrophages were incubated with media alone or 1 ⁇ g/ml R-848 in the presence of 0, 2.5, 5 or 10 ⁇ g/ml imiquimod for 6 hours.
- TNF was measured from triplicate cultures ⁇ SD and is representative of 3 separate donors, (c) Rheumatoid arthritis synovial fibroblasts were incubated with media alone or media containing 20 ⁇ g/ml Polyriboinosinic-polyribocytidylic acid (Poly IC) in the presence or 0 or 10 ⁇ g/ml imiquimod for 6 hours. Data shows triplicate cultures ⁇ SD and is representative of 3 separate donors.
- Poly IC Polyriboinosinic-polyribocytidylic acid
- Figure 4 illustrates that guanosine activates whereas cGMP and hypoxanthine do not activate macrophages to induce TNF production.
- Primary human M-CSF macrophages were incubated with media alone, 1 ⁇ g/ml R-848, 0.1-30 ⁇ g/ml guanosine or 10-30 ⁇ g/ml cGMP for 6 hours
- Human M-CSF macrophages were incubated with 0.1-20 ⁇ g/ml hypoxanthine for 6 hours.
- Figure 5 illustrates that loxoribine (figure 5a) and gardiquimod (figure 5b) have no effect on TNF production by primary human macrophages stimulated with lOng/ml LPS or 1 ⁇ g/ml R-848.
- Figure 6 illustrates the structure of loxoribine.
- Figure 7 illustrates the structure of gardiquimod.
- Figure 8 illustrates that loxoribine has no effect on spontaneous release of TNF from RA synovial membrane cultures from 6 donors.
- FIG. 9 illustrates that CL075 and CL097 increase TNF production in human M- CSF macrophages.
- FIG. 10 illustrates the structure of CL075.
- Figure 11 illustrates the structure of CL097.
- Figure 12 illustrates the structure of R-848.
- Cell culture reagents used were Penicillin-Streptomycin, RPMI 1640 and DMEM obtained from Cambrex (Belgium), Indomethacin from Sigma (USA) and FBS from PAA (Austria).
- the TLR ligands used were chloroform extracted Escherichia coli (E.coli) LPS and resiquimod (R-848), CpG (ODN 2006) and imiquimod from Invivogen (USA).
- Flagellin (purified), Pam 3 cys-ser(lys) 4 .3HCl (Pam3) and gardiquimod were from Alexis (UK). All reagents other than LPS were free from LPS contamination as assessed using the limulus amebocyte lysate (LAL) assay from Cambrex (USA).
- Sandwich ELISAs were employed to measure TNF and IL-6 (Pharmingen, UK).
- Absorbance was read on a spectrophotometric ELISA plate reader (Labsystems Multiscan Biochromic) and analyzed using Ascent software V2.6 (Thermo
- RA synovial membrane cells were isolated from patients undergoing joint replacement surgery as previously described (Foxwell et al., Proc. Natl. Acad. Sci. USA 95,8211-8215, 1998). All patients gave written informed consent and the study was approved by the local ethics committee. Immediately after isolation, cells were cultured at IxIO 5 cells/well in 96-well tissue culture plates (Falcon, UK) in RPMI 1640 containing 10% (v/v) FBS and 100 U/ml penicillin/streptomycin. Primary human synovial fibroblasts were cultured as described previously (Butler et al. Eur. Cytokine Netw. 5:441-8, 1994).
- Peripheral blood monocytes were isolated and cultured as previously described (Foxwell et al., Proc. Natl. Acad. Sci. USA 95, 8211- 8215, 1998). Macrophages were derived from monocytes after differentiation for 4 days with 100 ng/ml M-CSF (PeproTech, UK).
- Rheumatoid arthritis synovial membrane cells were also cultured in the presence of media alone or media containing l ⁇ g/ml and 5 ⁇ g/ml gardiquimod (see Figure 2). Gardiquimod enhances spontaneous TNF production.
- Example 2 The inhibitory effect of imiquimod being unexpected was investigated further. Although imiquimod is a TLR7 agonist it is structurally similar to R-848, a ligand for both TLRs 7 and 8. We therefore investigated if imiquimod could actually act as an inhibitor of TLR8 activity in human macrophages.
- M-CSF macrophages were also incubated with media alone or 1 ⁇ g/ml R-848 in the presence of 0, 2.5, 5 or 10 ⁇ g/ml imiquimod for 6 hours. TNF was measured from triplicate cultures ⁇ SD and is representative of 3 separate donors (see figure 3(b)).
- Rheumatoid arthritis synovial fibroblasts were incubated with media alone or media containing 20 ⁇ g/ml Poly IC in the presence or 0 or 10 ⁇ g/ml imiquimod for 6 hours. Data shows triplicate cultures ⁇ SD and is representative of 3 separate donors (see figure 3(c)).
- Imiquimod did inhibit TNF production induced by R848 (figure 3a) an effect that was dose dependent (Figure 3b). In contrast the drug had no effect on TNF production induced from macrophages by LPS (TLR4), Pam3Cys (TLR1,2) or flagellin (TLR5). Activation of TLR3 (Poly IC) induces no TNF or IL-6 production from human macrophages but does induce EL-6 from RA-synovial fibroblasts (data not shown). This also was not inhibited by imiquimod (Figure 3c). These results indicate that imiquimod inhibits TNF production in synovial membranes by blocking TLR8.
- Loxoribine and gardiquimod were no effect on TNF production (see figures 5a and 5b).
- Loxoribine and gardiquimod are structurally similar to imiquimod and, like imiquimod, they are also TLR7 ligands (see figures 6 and 7). However, the structural difference renders these molecules unable to inhibit TLR4 (LPS) and TLR8 (R-848) induced TNF.
- Loxoribine had no effect on spontaneous release of TNF (see figure 8).
- Loxoribine is structurally similar to imiquimod and like imiquimod it is also a TLR7 ligand.
- the lack of any inhibitory effect of loxoribine on the spontaneous production of TNF by rheumatoid arthritis synovial membrane cultures indicates that loxoribine would not be a useful treatment for rheumatoid arthritis.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof for use in treating inflammatory arthritis and related conditions. The present invention relates to the use of imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating inflammatory arthritis and related conditions. The present invention also relates to a kit comprising a pharmaceutical composition comprising imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof and instructions indicating that the composition is for use in treating inflammatory arthritis and related conditions. In addition, the present invention relates to a method of treating inflammatory arthritis and related conditions comprising administration of imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof. The method is preferably carried out on a subject in need of treatment. The inflammatory arthritis is preferably rheumatoid arthritis.
Description
Treatments for inflammatory arthritis
The present invention relates to imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof for use in treating inflammatory arthritis and related conditions. The present invention also relates to the use of imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating inflammatory arthritis and related conditions. The present invention also relates to a kit comprising a pharmaceutical composition comprising imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof and instructions indicating that the composition is for use in treating inflammatory arthritis and related conditions. In addition, the present invention relates to a method of treating inflammatory arthritis and related conditions comprising administration of imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof. The method is preferably carried out on a subject in need of treatment. The inflammatory arthritis is preferably rheumatoid arthritis.
Rheumatoid arthritis is a chronic inflammatory disease occurring in 0.5%-l% of the population. This disease affects the joints and is characterized by thickening of the synovial membrane. This disease leads to progressive debilitation in joint function which results in pain, disability, loss of man power and shorter life expectancy. In addition there are a number of similar related conditions; psoriatic arthritis, juvenile arthritis, ankylosing spondelytis, Crohn's disease and psoriasis.
Current treatments for rheumatoid arthritis have a number of disadvantages, including expense and/or severe side effects. At present, steroids such as dexamethasone and methyl-prednisolone, are widely used in the treatment of rheumatoid arthritis. While treatment with steroids can be effective, there are a number of serious side effects.
These side effects include hypertension, growth deficiencies in younger patients, osteoporosis, cataracts, psychosis, elevated blood sugar, glaucoma, etc. In addition, some patients are resistant to long-term use of steroids or become so with time.
New and alternative treatments currently used for rheumatoid arthritis are based on biologicals such as antibodies and soluble receptors. The most widely used of these is based on blocking TNF function with neutralizing antibodies or soluble receptors and has defined TNF as a key pathway in the inflammatory processes in rheumatoid arthritis. This type of anti-TNF therapy has been successful in the treatment of a number of diseases, with a substantial proportion of patients (approximately 60%) showing significant clinical benefit. Besides treating the inflammation, anti-TNF therapy also prevents joint destruction and thus is considered to have disease modifying anti-arthritic drug (DMARD) activity. However, it is extremely expensive and this places a heavy financial burden either on the patient or the healthcare system or both and this seriously limits availability. Many patients in the developed world and the majority in the developing world are not able to afford this treatment. In addition, possible side effects of anti-TNF therapy include anaphylaxis and cytopenia. Moreover systemic neutralisation of TNF leads to increased susceptibility to infection and the long-term effects are still unknown. Currently it is not possible to take anti- TNF drugs orally, which is a disadvantage. Moreover of those patients that do respond approximately 50% will become refractory to treatment in 2 years due to the development of immunity to the biological treatment.
Another class of drugs are the disease modifying anti-rheumatic drugs (DMARDS). An example of these is methotrexate, an anti-metabolite drug, which is widely used for the treatment of rheumatoid arthritis, psoriatic arthritis and psoriasis. Methotrexate has been successful in the treatment of these diseases, but can cause substantial side effects, such as severe skin reaction, infections such as pneumonia, severe damage to liver, kidneys, lungs and gastrointestinal tract. Again a significant number of patients do not respond or become refractory with time.
A number of DMARD pharmaceutical agents containing gold are also used in the treatment of rheumatoid arthritis. Examples of such agents include gold sodium thiomalate and auranofin. Potential side effects from being treated with antiinflammatory gold agents are oral ulcers, altered taste, serious skin rashes, renal
problems, inflammation of the intestines (enterocolitis), liver injury and lung disease. Furthermore, resistance to gold has been known to develop in patients.
A further class of drugs are the non-steroidal anti-inflammatory drugs (NSAID's). These are used to alleviate symptoms but not modify disease progression and includes the Cox 2 inhibitors "VIOXX"®, (a registered trademark of Merck & Co., Inc) and "CELEBREX" ®, (a registered trademark of G.D. Searle & Co). However there is major concern about the safety of these drugs with evidence of increased cardiovascular risk.
As a result of lack of efficacy, development of resistance, unacceptable side-effects and expense of existing treatments and route of administration, it is hugely desirable to find alternative treatments for rheumatoid arthritis. Thus there is a huge unmet medical need for an orally-available, well tolerated, inexpensive drug that could selectively block the production of TNF associated with pathological inflammation found in rheumatoid arthritis and related conditions.
The first aspect of the present invention provides imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof for use in treating inflammatory arthritis and related conditions.
Imiquimod ("ALDARA") has previously been known for treating certain diseases of the skin including genital herpes simplex virus, papilloma virus and skin cancer.
According to the present invention derivatives of imiquimod have the following structure:
wherein
R1 is -R2, -OR2, -NR2R3, -R2C(O)OR2 or -R2OC(O)R2;
R2 is a) alkyl, alkenyl or alkynyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxy, aryl, heteroaryl, carbocycle or heterocycle, wherein the aryl, heteroaryl, carbocycle or heterocycle is optionally substituted by one or more groups independently selected from C].6 alkyl, C1-6 alkoxy and halogen; or b) 5 to 7 membered aryl, heteroaryl, carbocycle or heterocycle, optionally substituted by one or more groups independently selected from C1-6 alkyl, C1-6 alkoxy and halogen; and
R3 is hydrogen or R2.
Imiquimod comprises the formula set out above wherein R1 is isobutyl.
The term "alkyl" as used herein means a straight or branched chain saturated hydrocarbon group, preferably with 1 to 10 carbons, more preferably 1 to 6 carbons, most preferably iso-butyl. The term "alkene" as used herein means a straight or branched chain unsaturated hydrocarbon group containing at least one carbon-carbon double bond. An alkene preferably has 2 to 10 carbons, more preferably 2 to 6 carbons. The term "alkyne" as used herein means a straight or branched chain
unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, preferably with 2 to 10 carbons, more preferably 2 to 6 carbons.
The term "carbocycle" as used herein means a cyclic hydrocarbon group which may be saturated or may contain one or more units of un-saturation, but which is not aromatic. A carbocycle is preferably 5-7 membered.
The term "heterocycle" as used herein means a cyclic group containing one or more species of heteroatom selected from the group consisting of a nitrogen atom, a sulphur atom and an oxygen atom. A heterocyclic group may be unsaturated or may contain one or more units of un-saturation, but is not aromatic. A heterocycle is preferably 5-7 membered.
The term "aryl group" used herein means an aryl group constituted by 5 to 10 carbon atoms, which may be monocyclic or bicyclic. Preferably, an aryl is 5-7 membered.
The term "heteroaryl" as used herein means an aromatic cyclic group containing one or more species of heteroatom selected from the group consisting of a nitrogen atom, a sulphur atom and an oxygen atom. Preferably, a heteroaryl is 5-7 membered.
The term "halogen" as used herein means preferably fluorine, chlorine, bromine or iodine.
Imiquimod or a derivative thereof may be provided as a pharmaceutically acceptable salt.
The inflammatory arthritis includes rheumatoid arthritis and the related conditions psoriatic arthritis, juvenile arthritis, ankylosing spondelytis but drugs are envisaged to be useful for other chronic diseases driven by TNF such as, Crohn's disease and psoriasis.
In a preferred embodiment the inflammatory arthritis is rheumatoid arthritis and the related conditions are psoriatic arthritis, juvenile arthritis, ankylosing spondelytis, Crohn's disease and psoriasis.
Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof according to the present invention inhibit TNF production.
Imiquimod and/or a derivative thereof and/or a pharmaceutically acceptable salt thereof and/or another agent may be used in combination, which may be for simultaneous, separate or sequential use.
In a further embodiment of the invention, imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof can be for topical administration.
In a yet further embodiment, imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof can be for oral administration. Where/if gastrointestinal toxicity occurs, the oral administration of imiquimod can be in combination with an agent that reduces the gastrotoxicity associated with imiquimod. The agent can be a prodrug of TLR7 agonists, such as ANA-975. Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof and an agent that reduces gastrotoxicity may be for simultaneous, separate or sequential use.
Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof may be used in combination with a further anti-inflammatory agent. Administration of imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof and other anti-inflammatory agent can be simultaneous, separate and/or sequential. Imiquimod, derivatives and/or salts thereof, in combination with another pharmaceutical agent, can act additively or synergistically.
The other anti-inflammatory agent may be termed a 5-HT receptor antagonist including promazine hydrochloride, ketanserine tartrate or mianserine hydrochloride, a serotonin reuptake inhibitor including fluoxetine hydrochloride, citalopram or
sertraline, an interferon inhibitor, a non-steroidal anti-inflammatory agent (NSAID), a disease modifying anti-rheumatic drug (DMARD), a biological agent (biologicals), a steroid, an immunosuppressive agent, a salicylate and/or a microbicidal agent. Nonsteroidal anti-inflammatory agents include anti-metabolite agents (including methotrexate) and anti-inflammatory gold agents (including gold sodium thiomalate, aurothiomalate or gold salts, such as auranofin). Biologicals include anti-TNF agents (including adalimumab, etanercept, infliximab, anti-EL-1 reagents, anti-IL-6 reagents, anti-B cell reagents (retoximab), anti-T cell reagents (anti-CD4 antibodies), anti-IL-15 reagents, anti-CLTA4 reagents, anti-RAGE reagents), antibodies, soluble receptors, receptor binding proteins, cytokine binding proteins, mutant proteins with altered or attenuated functions, RNAi, polynucleotide aptamers, antisense oligonucleotides or omega 3 fatty acids. Steroids include cortisone, prednisolone or dexamethasone. Immunosuppressive agents include cylcosporin, FK506, rapamycin, mycophenolic acid. Salicylates include aspirin, sodium salicylate, choline salicylate and magnesium salicylate. Microbicidal agents include quinine and hydroxychloroquine. For example, imiquimod and derivatives may be administered in combination with one or more of a 5-HT receptor antagonist, a serotonin reuptake inhibitor, an NSAID, DMARD or immunosuppressant.
In one embodiment, the further anti-inflammatory agent is administered orally (including buccally or sublingually) or parenterally (including subcutaneously, intramuscularly, intravenously or intradermally).
In a further embodiment, the invention provides the use of imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating inflammatory arthritis and related conditions.
The second aspect is a kit comprising a pharmaceutical composition comprising imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof and instructions indicating that the composition is for use in treating inflammatory arthritis and related conditions.
Compositions in accordance with the invention may be supplied as part of a sterile, pharmaceutical composition which will normally include a pharmaceutically acceptable carrier. This pharmaceutical composition may be in any suitable form. It may be provided in unit dosage form and will generally be provided in a sealed container. The kit of the invention may comprise a plurality of said unit dosage forms.
The oral pharmaceutical compositions may be presented as discrete units such as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids; or as edible foams or whips; or as emulsions). Suitable excipients for tablets or hard gelatine capsules include lactose, maize starch or derivatives thereof, stearic acid or salts thereof. Suitable excipients for use with soft gelatine capsules include for example vegetable oils, waxes, fats, semi-solid, or liquid polyols etc.
For the preparation of solutions and syrups, excipients which may be used include for example water, polyols and sugars. For the preparation of suspensions oils (e.g. vegetable oils) may be used to provide oil-in-water or water in oil suspensions.
The pharmaceutical compositions may contain preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, odourants, salts, buffers, coating agents or antioxidants. They may also contain further therapeutically active agents.
Route of administration may include; parenterally (including subcutaneous, intramuscular, intravenous, by means of, for example a drip patch), some further suitable routes of administration include (but are not limited to) oral (including buccal and sublingual), rectal, nasal, topical, infusion, vaginal, intradermal, intraperitoneally, intracranially, intrathecal and epidural administration or administration via oral or nasal inhalation, by means of, for example a nebuliser or inhaler, or by an implant.
For administration via the oral or nasal inhalation routes the may be delivered using a mechanical form including, but not restricted to, an inhaler or nebuliser device.
Further, where the oral or nasal inhalation routes are used, administration is by a SPAG (small particulate aerosol generator) may be used.
Dosages of the substances of the present invention can vary between wide limits, depending upon the condition to be treated, the health of the individual to be treated, etc. and a physician may determine appropriate dosages to be used. The dosage may be repeated as often as appropriate. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the imiquimod or derivative which produces a therapeutic effect
The compositions and uses described in this application are envisaged to have human, animal and veterinary applications. They are preferably applicable to mammals, in particular humans but are also applicable for use in production animals, in particular sheep, cows, pigs, chickens and goats, as well as companion animals, in particular cats and dogs and sporting animals, such as horses.
The third aspect of the invention is a method of treating inflammatory arthritis and related conditions comprising administering imiquimod, a derivative or a salt thereof. The derivative is defined according to the first aspect of the invention. In the third aspect of the invention, the method is preferably carried out on a subject in need of treatment.
In the present invention, the term "treatment" includes prophylactic treatment (i.e. prevention). In most circumstances, prevention of inflammatory arthritis or a related
condition is unlikely to be carried out. Usually, it is only when the presence of inflammatory arthritis or a related condition is diagnosed in a subject that prevention means are applied. However, prophylactic treatment may be appropriate if there is a known family history of significant inflammatory arthritis or a related condition or if tests (e.g. genetic tests) identify that an individual has a predisposition to inflammatory arthritis or a related condition.
The fourth aspect of the invention is imiquimod, a derivative or a salt thereof for treating inflammatory arthritis or a related condition.
Unless otherwise defined, all technical and scientific terms used herein have the meaning commonly understood by a person who is skilled in the art in the field of the present invention.
The preferred embodiments, as described for the first aspect of the invention, are the same for other aspects of the invention mutatis mutandis.
The present invention is described with reference to the figures, in which:
Figure 1 illustrates that imiquimod inhibits, R-848 increases and CpG has no effect on spontaneous TNF production from rheumatoid synovial cultures. Levels of TNF production are shown in ng/ml ± SEM from 7 - 12 unrelated RA patients.
Figure 2 illustrates that gardiquimod enhances spontaneous TNF production in rheumatoid synovial cultures. RA synovial membrane cells were incubated for 24 hours in the presence of media alone or media containing 1 or 5μg/ml gardiquimod (gard).
Figure 3 illustrates that imiquimod selectively inhibits activation of TLR8 signaling - (a) Primary human M-CSF macrophages were incubated with 10 μg/ml imiquimod alone or in combination with 10 ng/ml Flagellin, 10 ng/ml Pam3, 1 μg/ml R-848 or 10 ng/ml LPS for 6 hours. Data was pooled from triplicate wells from 3 separate donors
and shown as a percentage of the appropriate maximal responses (100%). (b) M-CSF macrophages were incubated with media alone or 1 μg/ml R-848 in the presence of 0, 2.5, 5 or 10 μg/ml imiquimod for 6 hours. TNF was measured from triplicate cultures ±SD and is representative of 3 separate donors, (c) Rheumatoid arthritis synovial fibroblasts were incubated with media alone or media containing 20 μg/ml Polyriboinosinic-polyribocytidylic acid (Poly IC) in the presence or 0 or 10 μg/ml imiquimod for 6 hours. Data shows triplicate cultures ±SD and is representative of 3 separate donors.
Figure 4 illustrates that guanosine activates whereas cGMP and hypoxanthine do not activate macrophages to induce TNF production. - (a) Primary human M-CSF macrophages were incubated with media alone, 1 μg/ml R-848, 0.1-30μg/ml guanosine or 10-30μg/ml cGMP for 6 hours, (b) Human M-CSF macrophages were incubated with 0.1-20μg/ml hypoxanthine for 6 hours.
Figure 5 illustrates that loxoribine (figure 5a) and gardiquimod (figure 5b) have no effect on TNF production by primary human macrophages stimulated with lOng/ml LPS or 1 μg/ml R-848.
Figure 6 illustrates the structure of loxoribine.
Figure 7 illustrates the structure of gardiquimod.
Figure 8 illustrates that loxoribine has no effect on spontaneous release of TNF from RA synovial membrane cultures from 6 donors.
Figure 9 illustrates that CL075 and CL097 increase TNF production in human M- CSF macrophages.
Figure 10 illustrates the structure of CL075.
Figure 11 illustrates the structure of CL097.
Figure 12 illustrates the structure of R-848.
The present invention is described with reference to the following non-limiting examples:
Examples
General Materials and Methods
Reagents
Cell culture reagents used were Penicillin-Streptomycin, RPMI 1640 and DMEM obtained from Cambrex (Belgium), Indomethacin from Sigma (USA) and FBS from PAA (Austria). The TLR ligands used were chloroform extracted Escherichia coli (E.coli) LPS and resiquimod (R-848), CpG (ODN 2006) and imiquimod from Invivogen (USA). Flagellin (purified), Pam3cys-ser(lys)4.3HCl (Pam3) and gardiquimod were from Alexis (UK). All reagents other than LPS were free from LPS contamination as assessed using the limulus amebocyte lysate (LAL) assay from Cambrex (USA).
ELISA (enzyme-linked immunosorbent assay).
Sandwich ELISAs were employed to measure TNF and IL-6 (Pharmingen, UK).. Absorbance was read on a spectrophotometric ELISA plate reader (Labsystems Multiscan Biochromic) and analyzed using Ascent software V2.6 (Thermo
Labsystems, Cambridge, United Kingdom). Cell viability was not significantly affected over this time period when examined by the 3-[4,5 dimethylthiazol-2-yl]-2,5- diphenyl-tetrazolium bromide (MTT) assay (Sigma).
Statistical methods
Mean, standard deviation (SD) and standard error of the mean (SEM) were calculated using GraphPad version 3 (GraphPad Software Inc., USA). For statistical analysis, a one tailed student's t-test of paired data was used with a 95% confidence interval.
SEM was used for pooled experimental data whilst SD was used in graphs showing representative experiments.
Cell culture
RA synovial membrane cells were isolated from patients undergoing joint replacement surgery as previously described (Foxwell et al., Proc. Natl. Acad. Sci. USA 95,8211-8215, 1998). All patients gave written informed consent and the study was approved by the local ethics committee. Immediately after isolation, cells were cultured at IxIO5 cells/well in 96-well tissue culture plates (Falcon, UK) in RPMI 1640 containing 10% (v/v) FBS and 100 U/ml penicillin/streptomycin. Primary human synovial fibroblasts were cultured as described previously (Butler et al. Eur. Cytokine Netw. 5:441-8, 1994). Peripheral blood monocytes were isolated and cultured as previously described (Foxwell et al., Proc. Natl. Acad. Sci. USA 95, 8211- 8215, 1998). Macrophages were derived from monocytes after differentiation for 4 days with 100 ng/ml M-CSF (PeproTech, UK).
Example 1
Rheumatoid arthritis synovial membrane cells were cultured for 24 hours in the presence of media alone or media containing lOμg/ml imiquimod, lμg/ml R-848 (resiquimod) or 2μM CpG. Supernatants were harvested and the level of TNF (n=16) was measured by ELISA. Addition of imiquimod led to a significant inhibition of TNF production by 47.3% ± 27 (p = 0.0101) (Figure 1). R-848 increases spontaneous TNF production and CpG has no effect. A student's paired t-test was used to analyse the data.
Rheumatoid arthritis synovial membrane cells were also cultured in the presence of media alone or media containing lμg/ml and 5μg/ml gardiquimod (see Figure 2). Gardiquimod enhances spontaneous TNF production.
Example 2
The inhibitory effect of imiquimod being unexpected was investigated further. Although imiquimod is a TLR7 agonist it is structurally similar to R-848, a ligand for both TLRs 7 and 8. We therefore investigated if imiquimod could actually act as an inhibitor of TLR8 activity in human macrophages.
Primary human M-CSF macrophages were incubated with 10 μg/ml imiquimod alone or in combination with 10 ng/ml Flagellin, 10 ng/ml Pam3, 1 μg/ml R-848 or 10 ng/ml LPS for 6 hours. Data was pooled from triplicate wells from 3 separate donors and shown as a percentage of the appropriate maximal responses (100%) (see figure 3(a)).
M-CSF macrophages were also incubated with media alone or 1 μg/ml R-848 in the presence of 0, 2.5, 5 or 10 μg/ml imiquimod for 6 hours. TNF was measured from triplicate cultures ±SD and is representative of 3 separate donors (see figure 3(b)).
Rheumatoid arthritis synovial fibroblasts (RASFs) were incubated with media alone or media containing 20 μg/ml Poly IC in the presence or 0 or 10 μg/ml imiquimod for 6 hours. Data shows triplicate cultures ±SD and is representative of 3 separate donors (see figure 3(c)).
Primary human M-CSF macrophages were also incubated with media alone, 1 μg/ml R-848, 0.1-30 μg/ml guanosine, 10-30μg/ml cGMP or 0.1-20 μg/ml hypoxanthine for 6 hours (see figure 4). TNF was measured from triplicate cultures ±SD.
Imiquimod did inhibit TNF production induced by R848 (figure 3a) an effect that was dose dependent (Figure 3b). In contrast the drug had no effect on TNF production induced from macrophages by LPS (TLR4), Pam3Cys (TLR1,2) or flagellin (TLR5). Activation of TLR3 (Poly IC) induces no TNF or IL-6 production from human macrophages but does induce EL-6 from RA-synovial fibroblasts (data not shown). This also was not inhibited by imiquimod (Figure 3c). These results indicate that imiquimod inhibits TNF production in synovial membranes by blocking TLR8.
Example 3
Primary human macrophages were stimulated with lOng/ml LPS or lμg/ml R-848 in the presence of loxoribine (purchased from Alexis (UK)) or gardiquimod (purchased from Invivogen (USA)).
Both loxoribine and gardiquimod had no effect on TNF production (see figures 5a and 5b). Loxoribine and gardiquimod are structurally similar to imiquimod and, like imiquimod, they are also TLR7 ligands (see figures 6 and 7). However, the structural difference renders these molecules unable to inhibit TLR4 (LPS) and TLR8 (R-848) induced TNF.
Example 4
The effect of loxoribine on rheumatoid arthritis synovial membrane cultures from 6 donors was tested.
Loxoribine had no effect on spontaneous release of TNF (see figure 8).
Loxoribine is structurally similar to imiquimod and like imiquimod it is also a TLR7 ligand. The lack of any inhibitory effect of loxoribine on the spontaneous production of TNF by rheumatoid arthritis synovial membrane cultures indicates that loxoribine would not be a useful treatment for rheumatoid arthritis.
Example 5
TLR7/8 ligands CL075 and CL097 were tested in primary human M-CSF macrophages.
CL075 and CL097 both increased TNF production (see figure 9), suggesting that it is unlikely that they would be useful for treating rheumatoid arthritis. The structures of CL075 and CL097 are illustrated in figures 10 and 11.
Claims
1. Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof for use in treating inflammatory arthritis or a related condition.
2. Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof for the use according to claim 1 , wherein the derivative has the following formula:
wherein
R1 is -R2, -OR2, -NR2R3, -R2C(O)OR2 or R2OC(O)R2;
R2 is a) alkyl, alkenyl or alkynyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxy, aryl, heteroaryl, carbocycle or heterocycle, wherein the aryl, heteroaryl, carbocycle or heterocycle is optionally substituted by one or more groups independently selected from Ci-6 alkyl, Ci-6 alkoxy and halogen; or b) 5 to 7 membered aryl, heteroaryl, carbocycle or heterocycle, optionally substituted by one or more groups independently selected from Ci -6 alkyl, Ci-6 alkoxy and halogen; and
R3 is hydrogen or R2. I o
3. Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof for the use according to claim 1 or claim 2, wherein the inflammatory arthritis is rheumatoid arthritis.
4. Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof for the use according to any one of claims 1 to 3, wherein imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof is for topical administration.
5. Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof for the use according to any one of claims 1 to 4, wherein imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof is administered in combination with a further anti-inflammatory agent.
6. Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof for the use according to claim 5, wherein the further anti-inflammatory agent is a 5-
HT receptor antagonist including promazine hydrochloride, ketanserine tartrate or mianserine hydrochloride, a serotonin reuptake inhibitor including fluoxetine hydrochloride, citalopram or sertraline, an interferon inhibitor, a non-steroidal anti-inflammatory agent (NSAED), a disease modifying anti-rheumatic drug (DMARD), a biological agent, a steroid, RNAi, aptamers, an immunosuppressive agent, a salicylate and/or a microbicidal agent.
7. Imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof for the use according to claims 5 or 6, wherein the further anti-inflammatory agent is for oral and/or parenteral administration.
8. The use of imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating inflammatory arthritis or a related condition.
9. A kit comprising a pharmaceutical composition comprising imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof and instructions indicating that the composition is for use in treating inflammatory arthritis or a related condition.
10. The kit of claim 9, wherein the derivative has the following formula:
wherein
R1 is -R2, -OR2, -NR2R3, -R2C(O)OR2 or R2OC(O)R2;
R2 is a) alkyl, alkenyl or alkynyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxy, aryl, heteroaryl, carbocycle or heterocycle, wherein the aryl, heteroaryl, carbocycle or heterocycle is optionally substituted by one or more groups independently selected from C i-6 alkyl, Ci-6 alkoxy and halogen; or b) 5 to 7 membered aryl, heteroaryl, carbocycle or heterocycle, optionally substituted by one or more groups independently selected from Ci-6 alkyl, Ci-6 alkoxy and halogen; and
R3 is hydrogen or R2.
11. This kit according to claim 9 or claim 10, wherein the inflammatory arthritis is rheumatoid arthritis.
12. The kit according to any one of claims 9 to 11, wherein imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof is for topical administration.
13. The kit according to any one of claims 9 to 12, wherein imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof is administered in combination with a further anti-inflammatory agent.
14. The kit according to claim 13, wherein the further anti-inflammatory agent is a 5-HT receptor antagonist including promazine hydrochloride, ketanserine tartrate or mianserine hydrochloride, a serotonin reuptake inhibitor including fluoxetine hydrochloride, citalopram or sertraline, an interferon inhibitor, a non-steroidal anti-inflammatory agent (NSAID), a disease modifying anti-rheumatic drug (DMARD), a biological agent, a steroid, RNAi, aptamers, an immunosuppressive agent, a salicylate and/or a microbicidal agent.
15. The kit of claims 13 or 14, wherein the further anti-inflammatory agent is for oral and/or parenteral administration.
16. A method of treating inflammatory arthritis or a related condition in a subject, comprising administration of imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof to the subject.
17. The method of claim 16, wherein the derivative has the following formula:
H wherein
R1 is -R2, -OR2, -NR2R3, -R2C(O)OR2 or R2OC(O)R2;
R2 is a) alkyl, alkenyl or alkynyl, optionally substituted by one or more substituents independently selected from the group consisting of halogen, hydroxy, aryl, heteroaryl, carbocycle or heterocycle, wherein the aryl, heteroaryl, carbocycle or heterocycle is optionally substituted by one or more groups independently selected from C1-6 alkyl, Ci-6 alkoxy and halogen; or b) 5 to 7 membered aryl, heteroaryl, carbocycle or heterocycle, optionally substituted by one or more groups independently selected from Ci-6 alkyl, Ci-6 alkoxy and halogen; and
R3 is hydrogen or R2.
18. The method of claim 16 or claim 17 wherein the subject is a mammal.
19. The method of claim 18, wherein the mammal is a human.
20. The method of any one of claims 16 to 19, wherein the inflammatory arthritis is rheumatoid arthritis.
21. The method according to any one of claims 16 to 20, wherein imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof is for topical administration.
22. The method according to any one of claims 16 to 21, wherein imiquimod, a derivative thereof or a pharmaceutically acceptable salt thereof is administered in combination with a further anti-inflammatory agent.
23. The method according to claim 22, wherein the further anti-inflammatory agent is a 5HT receptor antagonist including promazine hydrochloride, ketanserine tartrate or mianserine hydrochloride, a serotonin reuptake inhibitor including fluoxetine hydrochloride, citalopram or sertraline, an interferon inhibitor, a non- steroidal anti-inflammatory agent (NSAID), a disease modifying anti-rheumatic drug (DMARD), a biological agent, a steroid, RNAi, aptamers, an immunosuppressive agent, a salicylate and/or a microbicidal agent.
24. The method of claims 22 or 23, wherein the further anti-inflammatory agent is for oral and/or parenteral administration.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0715428.9 | 2007-08-08 | ||
| GBGB0715428.9A GB0715428D0 (en) | 2007-08-08 | 2007-08-08 | Compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009019473A1 true WO2009019473A1 (en) | 2009-02-12 |
Family
ID=38543217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2008/002671 WO2009019473A1 (en) | 2007-08-08 | 2008-08-05 | Treatments for inflammatory arthritis |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB0715428D0 (en) |
| WO (1) | WO2009019473A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8222270B2 (en) | 2008-12-19 | 2012-07-17 | Medicis Pharmaceutical Corporation | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod |
| US8598196B2 (en) | 2008-08-18 | 2013-12-03 | Medicis Pharmaceutical Corporation | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
| US8642616B2 (en) | 2009-07-13 | 2014-02-04 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| US9662347B2 (en) | 2010-05-11 | 2017-05-30 | Gachon University Of Industry-Academic Cooperation Foundation | Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system |
| JP2020517711A (en) * | 2017-04-27 | 2020-06-18 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 2-amino-quinoline derivative |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000247884A (en) * | 1999-03-01 | 2000-09-12 | Sumitomo Pharmaceut Co Ltd | Arachidonic acid-induced skin disease treatment |
| EP1104764A1 (en) * | 1998-08-12 | 2001-06-06 | Hokuriku Seiyaku Co., Ltd. | 1h-imidazopyridine derivatives |
| US20030078246A1 (en) * | 2001-07-09 | 2003-04-24 | Robyn Sackeyfio | Combinations for the treatment of inflammatory disorders |
| US20050004144A1 (en) * | 2003-04-14 | 2005-01-06 | Regents Of The University Of California | Combined use of IMPDH inhibitors with toll-like receptor agonists |
| WO2006074114A2 (en) * | 2005-01-03 | 2006-07-13 | Yu Ruey J | Compositions comprising o-acetylsalicyl derivatives of aminocarbohydrates and amino acids |
| WO2006091591A1 (en) * | 2005-02-22 | 2006-08-31 | The Regents Of The University Of California | Methods of treating gastrointestinal inflammation |
| WO2006130399A2 (en) * | 2005-06-01 | 2006-12-07 | 3M Innovative Properties Company | Therapeutic combinations and methods including irm compounds |
| EP1891953A1 (en) * | 2006-07-31 | 2008-02-27 | Meda AB | Immune response modifier sterile formulations and methods |
| WO2008090334A1 (en) * | 2007-01-22 | 2008-07-31 | Imperial Innovations Limited | Serotonin receptor antagonists for treating arthritis |
| WO2008090331A1 (en) * | 2007-01-22 | 2008-07-31 | Imperial Innovations Limited | Serotonin reuptake inhibitors for treating arthritis |
| WO2008098232A1 (en) * | 2007-02-08 | 2008-08-14 | Graceway Pharmaceuticals, Llc | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
-
2007
- 2007-08-08 GB GBGB0715428.9A patent/GB0715428D0/en not_active Ceased
-
2008
- 2008-08-05 WO PCT/GB2008/002671 patent/WO2009019473A1/en active Application Filing
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1104764A1 (en) * | 1998-08-12 | 2001-06-06 | Hokuriku Seiyaku Co., Ltd. | 1h-imidazopyridine derivatives |
| JP2000247884A (en) * | 1999-03-01 | 2000-09-12 | Sumitomo Pharmaceut Co Ltd | Arachidonic acid-induced skin disease treatment |
| US20030078246A1 (en) * | 2001-07-09 | 2003-04-24 | Robyn Sackeyfio | Combinations for the treatment of inflammatory disorders |
| US20050004144A1 (en) * | 2003-04-14 | 2005-01-06 | Regents Of The University Of California | Combined use of IMPDH inhibitors with toll-like receptor agonists |
| WO2006074114A2 (en) * | 2005-01-03 | 2006-07-13 | Yu Ruey J | Compositions comprising o-acetylsalicyl derivatives of aminocarbohydrates and amino acids |
| WO2006091591A1 (en) * | 2005-02-22 | 2006-08-31 | The Regents Of The University Of California | Methods of treating gastrointestinal inflammation |
| WO2006130399A2 (en) * | 2005-06-01 | 2006-12-07 | 3M Innovative Properties Company | Therapeutic combinations and methods including irm compounds |
| EP1891953A1 (en) * | 2006-07-31 | 2008-02-27 | Meda AB | Immune response modifier sterile formulations and methods |
| WO2008090334A1 (en) * | 2007-01-22 | 2008-07-31 | Imperial Innovations Limited | Serotonin receptor antagonists for treating arthritis |
| WO2008090331A1 (en) * | 2007-01-22 | 2008-07-31 | Imperial Innovations Limited | Serotonin reuptake inhibitors for treating arthritis |
| WO2008098232A1 (en) * | 2007-02-08 | 2008-08-14 | Graceway Pharmaceuticals, Llc | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
Non-Patent Citations (5)
| Title |
|---|
| BRENTANO ET AL: "The role of Toll-like receptor signalling in the pathogenesis of arthritis", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 233, no. 2, 1 February 2005 (2005-02-01), pages 90 - 96, XP005001598, ISSN: 0008-8749 * |
| DATABASE WPI Week 200064, Derwent World Patents Index; AN 2000-658704, XP002508459 * |
| GILLIET MICHEL ET AL: "Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.", ARCHIVES OF DERMATOLOGY DEC 2004, vol. 140, no. 12, December 2004 (2004-12-01), pages 1490 - 1495, XP002508458, ISSN: 0003-987X * |
| JURK M ET AL: "HUMAN TLR7 OR TLR8 INDEPENDENTLY CONFER RESPONSIVENESS TO THE ANTIVIRAL COMPOUND R-848", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 3, no. 6, 1 June 2002 (2002-06-01), pages 499, XP009000821, ISSN: 1529-2908 * |
| SACRE ET AL: "132 Toll-like Receptors (TLRS) Contribute in the Inflammation and Pathogenesis of RA", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 39, no. 1, 1 July 2007 (2007-07-01), pages 36, XP022328545, ISSN: 1043-4666 * |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9271973B2 (en) | 2008-08-18 | 2016-03-01 | Medicis Pharmaceutical Corporation | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
| US8598196B2 (en) | 2008-08-18 | 2013-12-03 | Medicis Pharmaceutical Corporation | Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy |
| US8236816B2 (en) | 2008-12-19 | 2012-08-07 | Medicis Pharmaceutical Corporation | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod |
| US8299109B2 (en) | 2008-12-19 | 2012-10-30 | Medicis Pharmaceutical Corporation | Method of treating actinic keratosis with 3.75% imiquimod cream |
| US11318130B2 (en) | 2008-12-19 | 2022-05-03 | Medicis Pharmaceutical Corporation | 2x2x2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
| US9370509B2 (en) | 2008-12-19 | 2016-06-21 | Medicis Pharmaceutical Corporation | 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod |
| US8222270B2 (en) | 2008-12-19 | 2012-07-17 | Medicis Pharmaceutical Corporation | 2×2×2 week treatment regimen for treating actinic keratosis with pharmaceutical compositions formulated with 2.5% imiquimod |
| US10238644B2 (en) | 2008-12-19 | 2019-03-26 | Medicis Pharmaceutical Corporation | 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod |
| US8642616B2 (en) | 2009-07-13 | 2014-02-04 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| US9980955B2 (en) | 2009-07-13 | 2018-05-29 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| US11850245B2 (en) | 2009-07-13 | 2023-12-26 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| US10238645B2 (en) | 2009-07-13 | 2019-03-26 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| US9078889B2 (en) | 2009-07-13 | 2015-07-14 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| US10918635B2 (en) | 2009-07-13 | 2021-02-16 | Medicis Pharmaceutical Corporation | Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts |
| US9662347B2 (en) | 2010-05-11 | 2017-05-30 | Gachon University Of Industry-Academic Cooperation Foundation | Method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of age-albumin in cells of the mononuclear phagocyte system |
| JP7179357B2 (en) | 2017-04-27 | 2022-11-29 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 2-amino-quinoline derivatives |
| JP2020517711A (en) * | 2017-04-27 | 2020-06-18 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 2-amino-quinoline derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0715428D0 (en) | 2007-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10092564B2 (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| RU2768120C2 (en) | Method for treating multiple sclerosis using lsd1 inhibitor | |
| US20250032461A1 (en) | Il-8 inihibitors for use in the treatment of some urological disorders | |
| WO2009019473A1 (en) | Treatments for inflammatory arthritis | |
| KR20230023717A (en) | TLR7 inhibitors in combination with prednisolone or hydroxychloroquine for the treatment of cutaneous lupus erythematosus | |
| WO2021190641A1 (en) | Methods for treating cytokine storm syndrome and related diseases | |
| JP2023126760A (en) | anti-inflammatory agent | |
| WO2022253034A1 (en) | Use of pyrrolopyrimidine compound | |
| WO2011131705A1 (en) | Treatment of multiple sclerosis with masitinib | |
| CN118403069A (en) | Therapeutic agent for nervous system diseases | |
| US20100273750A1 (en) | Serotonin receptor antagonists for treating arthritis | |
| IL297533A (en) | Consequences of glutrimide for use in the treatment of cough | |
| WO2008090331A1 (en) | Serotonin reuptake inhibitors for treating arthritis | |
| KR20240109355A (en) | Composition for preventing, ameliorating or treating upper respiratory inflammatory disease comprising povidone-iodine as effective component | |
| EP3621628B1 (en) | Method for treating multiple sclerosis using arsenic trioxide | |
| WO2007010946A1 (en) | Synovial cell proliferation inhibitor | |
| KR102320841B1 (en) | Composition for preventing and treating arthritis comprising niclosamide | |
| TW202448432A (en) | Treatment for amyotrophic lateral sclerosis (als) | |
| WO2019032672A1 (en) | Method for treating schnitzler's syndrome | |
| TW202404611A (en) | Methods of treating inflammation | |
| US20240423933A1 (en) | Drugs for treating neurodevelopmental disorders | |
| KR101844828B1 (en) | A composition for suppressing activation of mast cell comprising Cinnamaldehyde derivatives | |
| EA048070B1 (en) | TREATMENT METHODS FOR CUTANEOUS LUPUS ERYTHEMATOSUS | |
| WO2023202439A1 (en) | Use of diterpene compound derivative or salt thereof in preparation of medicine for preventing and treating atopic dermatitis | |
| EA043839B1 (en) | APPLICATION OF GLUTARIMIDE DERIVATIVE TO OVERCOMING RESISTANCE TO STEROIDS AND THERAPY OF DISEASES ASSOCIATED WITH ABERRANT INTERFERON GAMMA SIGNALING |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08776141 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08776141 Country of ref document: EP Kind code of ref document: A1 |